Founded in 2018, neoX Biotech is a next-generation biotech company at preclinical stage specializing in computational drug design for innovative therapeutics. By integrating artificial intelligence (AI), biophysics with high-throughput experiments, neoX aims to transform the research and development of macromolecular drugs and multi-specific drugs.
Through an in-depth characterization of protein-protein interaction (PPI), neoX has developed a highly transferable and sophisticated platform for novel drug discovery. NeoX has achieved demonstrable preclinical progress in a set of innovative drug pipelines derived from this platform.
Based on this PPI-based platform, neoX Biotech has collaborated with several pharmaceutical companies to develop collaborative pipelines in oncology and autoimmune diseases, potentially becoming First-in-Class or Best-in-Class drugs.
